Company: DVAX
Filing Date: 2025-04-04
Form Type: DEFA14A
Source: 0000930413-25-001154
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-04
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934</div>

Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:

| o | Preliminary Proxy Statement                                                     |
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| o | Definitive Proxy Statement                                                      |
| o | Definitive Additional Materials                                                 |
| x | Soliciting Material Pursuant to §240.14a-12                                     |

<div align='center'>Dynavax Technologies Corporation

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| x | No fee required.                                                                                    |
| o | Fee paid previously with preliminary materials.                                                     |
| o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11. |

This Schedule 14A filing consists of the
following press release relating to the potential contested director election at the 2025 Annual Meeting of Stockholders of Dynavax
Technologies Corporation (the “Company”) and the Company’s filing of its preliminary proxy statement in connection therewith.
The press release was first used or made available on April 3, 2025.

FOR IMMEDIATE RELEASE

<div align='center'>Dynavax Files Preliminary Proxy Statement

Dynavax’s Board is Overseeing Record Operational and Financial Performance

Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution</div>

EMERYVILLE, Calif., April 3, 2025 -- Dynavax Technologies Corporation
(Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and
commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”)
in connection with its upcoming Annual Meeting of Stockholders (“the 2025 Annual Meeting”). The preliminary proxy
statement is available on the investor relations section of the Company’s website at https://investors.dynavax.com/.

As described in the preliminary proxy filing, Dynavax’s